Market Intelligence, Clinical Progress, and High-Purity Reagents for Anti-Angiogenic and Ocular Disease Development.
ANGPT2 Biology and Target Background
Angiopoietin-2 (ANGPT2, UniProt O15123) is a key regulator of vascular remodeling and permeability. It acts primarily as an antagonist of the TIE2 receptor and contains a Fibrinogen C-terminal domain critical for receptor binding. Known mutations include variants associated with primary lymphedema (LMPHM10) that result in increased lymphangiogenesis or reduced secretion, and a common SNP (rs7813215). Understanding these molecular features is essential for designing selective therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANGPT2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANGPT2 Recombinant Protein (Human/Mouse/Cyno) – HEK293 expressed, >95% purity, Endotoxin <1 EU/µg, sequence verified, theoretical MW confirmed by LC-MS. | View ANGPT2 Products |
| Gene Delivery | ANGPT2 Promise-ORF / Lentivirus – Full-length ORF for stable cell line generation and autocrine expression studies. | View ANGPT2 Products |
| Benchmark Ab | Anti-ANGPT2 (Faricimab biosimilar / Nesvacumab sequence) – Recombinant positive control for binding and neutralization assays. | View ANGPT2 Products |
| Validator | ANGPT2 siRNA Set – For knockdown verification and assay specificity confirmation. | View ANGPT2 Products |
| Receptor | TIE2 (TEK) ECD-Fc Fusion Protein and Lentivirus – For SPR/BLI binding studies and stable cell line generation. | View TEK Products |
| Counter-Screening Antigen | ANGPT1 Recombinant Protein – For selectivity assays against ANGPT2-specific therapeutics. | View ANGPT1 Products |
| Pathway Partner A | VEGFA – Synergistic angiogenic driver; co-target in bispecific strategies (e.g., Faricimab). | View VEGFA Products |
| Pathway Partner B | DLL4 – Alternative angiogenic pathway for combination studies. | View DLL4 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species evaluation (cyno/mouse preclinical translation) | Human / Mouse / Cyno ANGPT2 ortholog proteins available with >95% purity; sequence verified for epitope conservation. |
| ANGPT1 subfamily counter screening (avoiding TIE2 agonist neutralization) | High-purity ANGPT1 protein strictly verified by mass spec; activity controls included. |
| Receptor interaction and blocking assays | HEK293 expressed proteins with native glycosylation ensure proper tertiary structure. |
| High-concentration stability (intravitreal formulation) | Low-endotoxin (<1 EU/µg) aggregation-tested proteins suitable for viscosity / concentration studies. |
| Lack of controls | Clinical Benchmark Antibodies (Faricimab-class biosimilars) included. |
| False positives | Validated siRNA included for target specificity checks. |
Live ANGPT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ANGPT2 therapeutics is intensifying, with major players shifting focus from traditional monospecific antibodies to bispecific antibodies and sustained-release biologics. First-generation antibodies such as Nesvacumab (Pfizer) established proof-of-mechanism, while Roche's Faricimab (VEGF-A/ANGPT2 bispecific) has been approved for wet AMD and DME, demonstrating superior durability over anti-VEGF monotherapy. Current clinical expansion targets oncology indications where ANGPT2-driven vascular normalization may enhance immune cell infiltration. Next-generation modalities explore extended half-life formulations, Sub-Q delivery for oncology, and gene therapy for chronic retinal diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific mAb (VEGF/ANGPT2) | Roche (Faricimab) | nAMD, DME, Diabetic Retinopathy | Heterodimer validation; need high-purity ANGPT2 + VEGF-A cross-reactive proteins; TIE2 lentivirus for functional blocking assays. |
| Monoclonal Antibody | Pfizer (Nesvacumab), Regeneron, Amgen | Solid tumors (combo therapies), DME | ANGPT1 counter-screening; Cyno cross-reactivity; strict endotoxin control. |
| Peptibody / Fusion | Amgen | Oncology | Ligand capture & blocking assay; need domain-defined ANGPT2 protein. |
| Gene Therapy (AAV) | Experimental | Chronic retinal diseases | siRNA validation tools for target engagement proof. |